Answers are grounded in this paper and cite their sources.
Analysis shows recurrence timing post-neoadjuvant chemotherapy in triple-negative breast cancer, suggesting monitoring strategies.
Distribution of Events After Neoadjuvant Chemotherapy Across Five Trials stratified by 6-month intervals. A) Patients with pathologic complete response. B) Patient with residual disease. Time is calculated from randomization (i.e., initiation of neoadjuvant therapy).
No takes yet. Share an insight, caveat, or question.
Licata et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: